Reduced illness incidence — clinically demonstrated
A new clinical study on Spectramune® (announced 2025) demonstrated statistically significant reduction in the incidence of illness vs. placebo — one of the most compelling outcomes possible for an immune supplement. Rather than just showing improved immune biomarkers, Spectramune® reduces the actual probability of getting sick, which is the outcome consumers ultimately care about.
Less severe symptoms when illness occurs
Beyond reducing illness frequency, Spectramune® also reduces symptom severity when illness does occur — shortening duration and reducing the impact on daily function. This dual outcome (fewer illnesses + milder symptoms) positions Spectramune® as comprehensive immune protection rather than just immune stimulation.
Broad-spectrum immune defense
Spectramune®'s multi-ingredient approach addresses multiple aspects of immune defense — innate immune activation, mucosal barrier support, antioxidant protection, and adaptive immune priming — providing comprehensive protection relevant to the multiple pathways through which infections occur and progress.
Multi-pathway immune defense and barrier support
Spectramune® combines ingredients with complementary immune mechanisms — innate immune stimulation (NK cell and macrophage activation), mucosal barrier reinforcement (secretary IgA and tight junction support), antioxidant protection of immune cells (reducing oxidative burden on immune response), and trained immunity induction (preparing faster adaptive responses to future challenges). The multi-pathway approach produces broader and more robust immune protection than single-mechanism immune ingredients.
Randomized, double-blind, placebo-controlled trial of Spectramune® demonstrating reduced incidence of illness and less severe symptoms. Published/announced 2025.
Adults during immune challenge season. Placebo-controlled design.
Spectramune® significantly reduced illness incidence vs. placebo. Subjects who did become ill showed less severe symptoms and shorter illness duration. Statistically significant protective outcomes confirmed for both illness frequency and severity. Well-tolerated.